Literature DB >> 6984902

Endralazine in patients with severe hypertension and renal insufficiency.

E R Higgs, P R Harrison, R A Banks, J C Kingswood, J C Mackenzie.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6984902      PMCID： PMC2426600          DOI： 10.1136/pgmj.58.686.767

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN： 0032-5473            Impact factor:   2.401


× No keyword cloud information.
  5 in total

1.  The effect of treatment on the vascular deterioration associated with hypertension, with particular emphasis on renal function.

Authors:  J H MOYER; C HEIDER; K PEVEY; R V FORD
Journal:  Am J Med       Date:  1958-02       Impact factor: 4.965

Review 2.  Late toxicity to hydralazine resembling systemic lupus erythematosus or rheumatoid arthritis.

Authors:  H M Perry
Journal:  Am J Med       Date:  1973-01       Impact factor: 4.965

3.  Relationship of acetyl transferase activity to antinuclear antibodies and toxic symptoms in hypertensive patients treated with hydralazine.

Authors:  H M Perry; E M Tan; S Carmody; A Sakamoto
Journal:  J Lab Clin Med       Date:  1970-07

4.  An improved and simplified method of detecting the acetylator phenotype.

Authors:  D A Evans
Journal:  J Med Genet       Date:  1969-12       Impact factor: 6.318

5.  Hydrallazine in hypertension: is there a safe dose?

Authors:  R F Bing; G I Russell; H Thurston; J D Swales
Journal:  Br Med J       Date:  1980-08-02
  5 in total
  1 in total

1.  Evaluation of once daily endralazine in hypertension.

Authors:  R Wu; J D Spence; S G Carruthers
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.